List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 8 studies with search of: boceprevir
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Enrolling by invitation Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (Study P05514AM1)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir;   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908)
2 Active, not recruiting Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908);   Drug: Boceprevir placebo
3 Active, not recruiting Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM1)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908);   Drug: Boceprevir placebo
4 Not yet recruiting A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411AM1)
Conditions: HIV Infections;   Hepatitis C;   HCV Infection
Interventions: Drug: PEG2b plus ribavirin followed by placebo;   Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
5 Enrolling by invitation Three-year Follow-up of Subjects After Administration of Boceprevir for the Treatment of Chronic Hepatitis C (Study P05063)
Conditions: Hepatitis C, Chronic;   Hepacivirus
Interventions: Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 054031);   Drug: Ribavirin (SCH 018908);   Drug: Placebo
6 Active, not recruiting Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir;   Other: Placebo;   Biological: Peginterferon alfa-2a;   Drug: Ribavirin
7 Completed Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523AM2)(COMPLETED)
Condition: Chronic Hepatitis C
Interventions: Drug: SCH 503034 (boceprevir);   Drug: peginterferon-alfa 2b;   Drug: ribavirin 200 mg capsules in doses of 800 to 1400 mg/day;   Drug: ribavirin 200 mg capsules in doses of 400 to 1000 mg/day
8 Completed SCH 503034 Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659)(COMPLETED)
Condition: Chronic Hepatitis C
Intervention: Drug: SCH 503034

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services